Core Viewpoint - Seacross Pharma (Europe) Ltd., a subsidiary of the company, has received marketing authorization for its injectable Teicoplanin from the Italian Medicines Agency and the Dutch Health Products Regulatory Authority, indicating a significant regulatory achievement for the company [1] Group 1: Product Information - Injectable Teicoplanin is primarily used for treating both adult and pediatric patients with parenteral infections, including complex skin and soft tissue infections, bone and joint infections, acquired pneumonia, urinary tract infection complications, infectious endocarditis, and peritoneal dialysis-related peritonitis [1] - The product is also indicated for the treatment of Clostridium difficile-associated diarrhea and colitis [1]